Latamoxef-induced coagulation disorders: Incidence and risk factors.
Adult
Age Factors
Aged
Anti-Bacterial Agents
/ adverse effects
Blood Coagulation
/ drug effects
Blood Coagulation Disorders
/ chemically induced
Ceftazidime
/ adverse effects
Comorbidity
Female
Hemorrhage
/ chemically induced
Humans
Incidence
Male
Middle Aged
Moxalactam
/ adverse effects
Retrospective Studies
Risk Factors
Sex Factors
bleeding
coagulation disorders
latamoxef
Journal
Journal of clinical pharmacy and therapeutics
ISSN: 1365-2710
Titre abrégé: J Clin Pharm Ther
Pays: England
ID NLM: 8704308
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
revised:
15
04
2021
received:
14
03
2021
accepted:
19
04
2021
pubmed:
12
6
2021
medline:
12
1
2022
entrez:
11
6
2021
Statut:
ppublish
Résumé
To observe the effect of latamoxef on coagulation function and to analyse its risk factors. A retrospective cohort study was performed to compare patients receiving latamoxef versus those treated with ceftazidime. Baseline characteristics and coagulation parameters were recorded and analysed to explore whether treatment with latamoxef increased the risks of coagulation disorders and bleeding. A total number of 162 patients receiving latamoxef and 93 patients receiving ceftazidime were included. Haemorrhagic events were similar between groups, but patients receiving latamoxef had a higher risk of coagulation disorders compared to those receiving ceftazidime. Multivariate analysis revealed that the exposure of antibiotics, especially the cumulative defined daily doses (DDDs), and the nutrition risk may be the predictors of coagulation disorders. Latamoxef might induce coagulation disorders. Cumulative DDDs and the nutrition risk were linked with coagulation disorders.
Substances chimiques
Anti-Bacterial Agents
0
Ceftazidime
9M416Z9QNR
Moxalactam
VUF6C936Z3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1382-1386Subventions
Organisme : Key Research and Development Program of Shaanxi
ID : 2021KW-65
Organisme : Key Research and Development Program of Shaanxi
ID : 2021SF-179
Organisme : National Natural Science Foundation of China
ID : 81603175
Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Park GH, Kim S, Kim MS, et al. The association between cephalosporin and hypoprothrombinemia: a systematic review and meta-analysis. Int J Environ Res Public Health. 2019;16(20):3937.
Wang W, Liu Yi YUC, Tan J, et al. Cefoperazone-sulbactam and risk of coagulation disorders or bleeding: a retrospective cohort study. Expert Opin Drug Saf. 2020;19(3):339-347.
Chan-Lui WY, Stroebel AB, Yeung CY. Hemorrhagic tendency as a complication of Moxalactam therapy in bacterial meningitis. Brain Dev. 1983;5(4):417-420.
Zhu Y, Shen J, Wu W, Sun X, Hu X. Latamoxef induced a severe coagulation disorder in older patients in China: two case reports. J Clin Pharm Ther. 2021;46(1):227-229.
Hu HR. Fatal Vitamin K-dependent coagulopathy associated with cefoperazone/sulbactam: a case report. Drug Saf Case Rep. 2019;6(1):6.
Schentag JJ, Welage LS, Grasela TH, Adelman MH. Determinants of antibiotic-associated hypoprothrombinemia. Pharmacotherapy. 1987;7(3):80-86.
Strom BL, Schinnar R, Gibson GA, Brennan PJ, Berlin JA. Risk of bleeding and hypoprothrombinaemia associated with NMTT side chain antibiotics: using cefoperazone as a test case. Pharmacoepidemiol Drug Saf. 1999;8(2):81-94.
Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M. Enhanced bleeding with cefoxitin or moxalactam. Statistical analysis within a defined population of 1493 patients. Arch Intern Med. 1986;146(11):2159-2164.
Yangco BG, Baird I, Lorber B, et al. Comparative efficacy and safety of ceftizoxime, cefotaxime and latamoxef in the treatment of bacterial pneumonia in high risk patients. J Antimicrob Chemother. 1987;19(2):239-248.
Baxter JG, Marble DA, Whitfield LR, Wels PB, Walczak P, Schentag JJ. Clinical risk factors for prolonged PT/PTT in abdominal sepsis patients treated with moxalactam or tobramycin plus clindamycin. Ann Surg. 1985;201(1):96-102.
Calandra GB, Hesney M, Grad C. A multiclinic randomized study of the comparative efficacy, safety and tolerance of imipenem/cilastatin and moxalactam. Eur J Clin Microbiol. 1984;3(5):478-487.
Fainstein V, Bodey GP, McCredie KB, et al. Coagulation abnormalities induced by beta-lactam antibiotics in cancer patients. J Infect Dis. 1983;148(4):745-750.
Weitekamp MR, Caputo GM, Al-Mondhiry HA, Aber RC. The effects of latamoxef, cefotaxime, and cefoperazone on platelet function and coagulation in normal volunteers. J Antimicrob Chemother. 1985;16(1):95-101.
Bowcock S, Mackie IJ, Ho D, Moulsdale M, Billings P, Machin SJ. Effects of various doses of latamoxef (moxalactam) on haemostasis. J Hosp Infect. 1986;8(2):193-199.
Chen L-J, Hsiao F-Y, Shen L-J, et al. Use of hypoprothrombinemia-inducing cephalosporins and the risk of hemorrhagic events: a nationwide nested case-control study. PLoS One. 2016;11(7):e0158407.
Shirakawa H, Komai M, Kimura S. Antibiotic-induced vitamin K deficiency and the role of the presence of intestinal flora. Int J Vitam Nutr Res. 1990;60(3):245-251.